Evidence map›Paper›PMID 25152775›Full record

ArticleNanoethics2014

Making Common Sense of Vaccines: An Example of Discussing the Recombinant Attenuated

Dorothy J Dankel, Kenneth L Roland, Michael Fisher, Karen Brenneman, Ana Delgado, Javier Santander, Chang-Ho Baek, Josephine Clark-Curtiss, Roger Strand, Roy Curtiss

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoethics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Dorothy J DankelThe Centre for the Study of the Science and the Humanities, University of Bergen, Allégaten 34, Post Box 7805, 5020 Bergen, Norway.
Kenneth L RolandThe Biodesign Institute, Center for Infectious Diseases and Vaccinology, Arizona State University, 1001 S McAllister Avenue, Tempe, AZ 85287 USA.
Michael FisherThe Biodesign Institute, Center for Infectious Diseases and Vaccinology, Arizona State University, 1001 S McAllister Avenue, Tempe, AZ 85287 USA.
Karen BrennemanThe Biodesign Institute, Center for Infectious Diseases and Vaccinology, Arizona State University, 1001 S McAllister Avenue, Tempe, AZ 85287 USA.
Ana DelgadoThe Centre for the Study of the Science and the Humanities, University of Bergen, Allégaten 34, Post Box 7805, 5020 Bergen, Norway.
Javier SantanderNucleus for Microbiology and Immunity, Center for Genomics and Bioinformatics and The School of Life Sciences, Universidad Mayor, Chile and Arizona State University, Camino la Piramide 5750, Huechuraba, 8580745 Chile.
Chang-Ho BaekSynthetic Biology R&D, Bioscience Division, Life Science Solutions Group (LSG), Thermo Fisher Scientific, 5791 Van Allen Way, Carlsbad, CA 92008 USA.
Josephine Clark-CurtissThe Biodesign Institute, Center for Infectious Diseases and Vaccinology, Arizona State University, 1001 S McAllister Avenue, Tempe, AZ 85287 USA.
Roger StrandThe Centre for the Study of the Science and the Humanities, University of Bergen, Allégaten 34, Post Box 7805, 5020 Bergen, Norway.
Roy CurtissThe Biodesign Institute, Center for Infectious Diseases and Vaccinology, Arizona State University, 1001 S McAllister Avenue, Tempe, AZ 85287 USA.
Arizona State University · USUniversity of Bergen · NOThermo Fisher Scientific (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Researchers have iterated that the future of synthetic biology and biotechnology lies in novel consumer applications of crossing biology with engineering. However, if the new biology's future is to be sustainable, early and serious efforts must be made towards social sustainability. Therefore, the crux of new applications of synthetic biology and biotechnology is public understanding and acceptance. The RASVaccine is a novel recombinant design not found in nature that re-engineers a common bacteria (

Indexed as

BiotechnologyEthicsLegal issuesSocial aspectsSocietal valuesSocietyTrustVaccineValues

Identifiers

PMID25152775
PMCPMC4129221
OpenAlexW1971227225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.